Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib

Leukemia

Volumn 26, Issue 5, 2012, Pages 977-984

  Janssen, J J W M ^a   Deenik, W ^b   Smolders, K G M ^a   Van Kuijk, B J ^a   Pouwels, W ^a   Kelder, A ^a   Cornelissen, J J ^b   Schuurhuis, G J ^a   Ossenkoppele, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CML; flow cytometry; imatinib; stem cells

Indexed keywords

BCR ABL PROTEIN; CD11B ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD7 ANTIGEN; IMATINIB; THY 1 ANTIGEN;

ARTICLE; BLOOD TOXICITY; BONE MARROW; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CD34 SELECTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING UNIT; CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LIQUID CULTURE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STEM CELL; TREATMENT RESPONSE;

EID: 84860745453     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.347     Document Type: Article

References (35)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
2. Cortes J, O'Brien S, Borthakur G, Jones D, Ravandi F, Koller C et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annu Meet Abstr 2008; 112: 182.
3. Cortes J, O'Brien S, Jones D, Ferrajoli A, Konopleva M, Borthakur G et al. Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). ASH Annu Meet Abstr 2008; 112: 446.
4. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
5. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
6. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
7. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539.
8. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML. N Engl J Med 2004; 351: 657-667.
9. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926-935.
10. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064-4072.
11. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697-704.
12. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006; 108: 1370-1373.
13. van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S et al. Aberrant marker expression patterns on the CD34+. Leukemia 2007; 21: 1700-1707.
14. Terwijn M, Kelder A, Rutten AP, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. Specific detection of aberrant and normal stem cells in acute myeloid leukemia patients opens the way for defining highly specific targets for stem cell therapy. ASH Annu Meet Abstr 2008; 112: 1353.
15. van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007; 110: 2659-2666.
16. Sutherland H, Blair A, Vercauteren S, Zapf R. Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long-term proliferation in vitro. Br J Haematol 2001; 114: 296-306.
17. van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, Broxterman HJ et al. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003; 88: 983-993.
18. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350.
19. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330-3338.
20. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308: 1493-1498.
21. Deenik W, Janssen JJWM, van der HB, Verhoef GE, Smit WM, Kersten MJ et al. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica 2010; 95: 914-921.
22. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051.
23. Eaves CJ, Cashman JD, Zoumbos NC, Barnett MJ, Eaves AC. Biological strategies for the selective manipulation of normal and leukemic stem cells. Stem Cells 1993; 11 Suppl 3: 109-121.
24. Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003-1010.
25. Delforge M, Boogaerts MA, McGlave PB, Verfaillie CM. BCR/ABL-CD34(+)HLA- DRprogenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Blood 1999; 93: 284-292.
26. Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G et al. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 1993; 81: 801-807.
27. Pratt G, Rawstron AC, English AE, Johnson RJ, Jack AS, Morgan GJ et al. Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve. Br J Haematol 2001; 114: 937-943.
28. +/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haematol 2002; 117: 238-244.
29. Specchia G, Pastore D, Mestice A, Liso A, Carluccio P, Leo M et al. Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients. Acta Haematol 2006; 116: 229-237.
30. Buccisano F, Rossi FM, Venditti A, Del Poeta G, Cox MC, Abbruzzese E et al. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol 2004; 125: 203-212.
31. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008; 322: 1861-1865.
32. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
33. Lanza F, Bi S, Castoldi G, Goldman JM. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Leukemia 1993; 7: 1570-1575.
34. Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005; 19: 435-441.
35. Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99: 680-693.